Table 2.
Crude and adjusted hazard ratio (HRs) for potential factors related to relapse ofP. vivaxmalaria
|
Crude (n = 53) |
Adjusted* (n = 48) |
|||||
|---|---|---|---|---|---|---|
| |
|
Model 1 |
Model 2 |
|||
| HR [CI 95%] | p (Wald) | HR [CI 95%] | p (Wald) | HR [CI 95%] | p (Wald) | |
|
Gender |
|
|
|
|
|
|
| Men |
2.36 [0.69–8.07] |
0.17 |
2.23 [0.63-7.84] |
0.21 |
3.9 [0.59-26.81] |
0.16 |
| Women |
1 |
|
1 |
|
1 |
|
|
Age (years) ** |
0.97 [0.93-1.02] |
0.25 |
0.95 [0.90-1.01] |
0.09 |
0.94 [0.89-0.99] |
0.03 |
|
Adverse drug events (ADE) |
|
|
|
|
|
|
| Yes |
0.39 [0.09-1.74] |
0.22 |
- |
- |
- |
- |
| No |
1 |
|
- |
- |
- |
- |
|
Duration of primaquine therapy |
|
|
|
|
|
|
| Short regimen |
1 |
0.18 |
1 |
0.14 |
1 |
0.04 |
| Long regimen |
0.46 [0.15-1.42] |
|
0.42 [0.13-1.33] |
|
0.28 [0.08-0.98] |
|
|
Primaquine total dose adjusted by weight |
|
|
|
|
|
|
| Yes (≥ 3.2 mg/kg) |
1 |
0.03 |
1 |
0.04 |
- |
- |
| No (< 3.2 mg/kg) |
2.94 [1.09-8.33] |
|
3.13 [1.08-9.09] |
|
- |
- |
|
Primaquine total dose (mg/kg) |
|
|
|
|
|
|
|
< 3.6 |
5.24 [0.68-40.15] |
0.24 |
- |
- |
9.36 [1.06-82.23] |
0.04 |
|
3.6 – 4.1 |
1 |
|
- |
- |
1 |
|
|
> 4.1 |
7.09 [0.64-78.74] |
|
- |
- |
15.4 [0.79-300.57] |
0.07 |
|
Concordance |
- |
- |
0.73 |
|
0.75 |
|
|
R square |
- |
- |
0.23 |
|
0.28 |
|
| p (Wald) | - | - | 0.06 | 0.08 | ||
* Cox regression models. **Continuous variable.